Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Vitamin D Increases Survival of Breast Cancer Patients

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Print article
Breast cancer patients with high levels of vitamin D in their blood have been found to be twice as likely to survive the disease as women with low levels of this nutrient, according to new research.

According to the US National Institutes of Health (NIH; Bethesda, MD, USA), the current recommended daily allowance for vitamin D is 600 IU for adults and 800 IU for people over 70 years old.

University of California, San Diego School of Medicine (La Jolla, USA) researchers reported their findings in the March 2014 issue of the journal Anticancer Research. In earlier research, Cedric F. Garland, DrPH, professor in the department of family and preventive medicine, showed that low vitamin D levels were linked to a high risk of premenopausal breast cancer. That finding, he said, prompted him to question the relationship between 25-hydroxyvitamin D—a metabolite produced by the body from the ingestion of vitamin D—and breast cancer survival rates.

Dr. Garland and colleagues performed a statistical analysis of five studies of 25-hydroxyvitamin D obtained at the time of patient diagnosis and their follow-up for a median of nine years. Combined, the studies included 4,443 breast cancer patients. “Vitamin D metabolites increase communication between cells by switching on a protein that blocks aggressive cell division,” said Dr. Garland. “As long as vitamin D receptors are present tumor growth is prevented and kept from expanding its blood supply. Vitamin D receptors are not lost until a tumor is very advanced. This is the reason for better survival in patients whose vitamin D blood levels are high.”

Women in the high serum group had an average level of 30 ng/mL of 25-hydroxyvitamin D in their blood. The low group averaged 17 ng/mL. The average level in patients with breast cancer in the United States is 17 ng/mL. “The study has implications for including vitamin D as an adjuvant to conventional breast cancer therapy,” said coauthor Heather Hofflich, DO, UC San Diego associate professor in the department of medicine.

Garland recommended randomized controlled clinical trials to confirm the findings but suggested physicians consider adding vitamin D into a breast cancer patient’s standard care now and then closely monitor the patient. “There is no compelling reason to wait for further studies to incorporate vitamin D supplements into standard care regimens since a safe dose of vitamin D needed to achieve high serum levels above 30 ng/mL has already been established,” said Dr. Garland.

A 2011 meta-analysis by Dr. Garland and colleagues estimated that a serum level of 50 ng/mL is tied to a 50% lower risk of breast cancer. Whereas there are some variations in absorption, those who consume 4,000 International Units (IU) per day of vitamin D from food or a supplement typically would reach a serum level of 50 ng/ml. Dr. Garland advised patients to ask their healthcare provider to measure their levels before substantially increasing vitamin D intake.

Related Links:

University of California, San Diego School of Medicine



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.